Dr. Rose Maase studied chemistry at the University of Manchester (UK) where she obtained her BSc (2000) and PhD (2004), after which she worked for Unilever Foods UK. Since 2008 she has been working in the field of newborn screening (NBS), initially as (Senior) Clinical Scientist at the Metabolic Laboratory of Hamad Medical Corporation in Qatar, where she was responsible for the development of Laboratory Developed Tests required for the specific needs of the Qatari population. In 2015 she joined the team of scientists at the Reference Laboratory for NBS at the Dutch National Institute for Public Health and the Environment (RIVM). In this role she has been technical project leader for several implementation projects, such as NBS program expansion in 2019 (CPT 1, PA and MMA) and in 2021 (MPS I), as well as for many optimization and innovation projects related to the routine NBS program. In her current role as a senior scientist at RIVM she is focused primarily on the signaling and innovations for the Dutch NBS program. She is a member of the Dutch Workgroup for Research for Newborn Screening (WONHS), the Dutch Advisory Committee on Neonatal screening for Metabolic Diseases (ANS-MZ, (2020-2024)), the Dutch Program Committee for Neonatal screening (PNHS), the Association of Public Health Laboratories (APHL) NewSTEPs New Disorders workgroup and the CLIR Collaborator Group. In addition, Rose is periodically involved in meetings of the Dutch Health Council as consulted expert.